Tiffany Beauvais

Tiffany Beauvais

Auto-generated profile, based on publicly available information

Tiffany Beauvais

INCIT, INSERM 1302, Labex IGO, Universitéd’Angers, Nantes Université

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 August 2025 in OncoImmunology
Verified
Journal Article
Open access
EDEmilie Dupré
Emilie Dupré
AGAmélie Guiho
Amélie Guiho
TBTiffany Beauvais
Tiffany Beauvais
LLLéna Labous
Léna Labous
Tristan CardonTristan Cardon
Tristan Cardon
FLFrançois Lang
François Lang
The search for reliable shared tumor-specific antigens (TSAs) to improve cancer immunotherapy is on-going. The so-called non-coding regions of the genome have recently been shown to give rise to immunogenic peptides, including the melanoma-specific antigen MELOE-1 which is translated from the long intergenic non-coding RNA (lincRNA) meloe in an IRES-dependent manner. Here, we present a strategy to systematically identify tumor-specific antigens produced by ORFs within lincRNAs with IRES-like upstream structures. We provide evidence suggesting that in the melanocytic lineage a significant proportion of the selected lincRNAs can produce immunogenic peptides. T cell repertoires against some of these peptides were found in peripheral blood mononuclear cells (PBMCs) from healthy donors and melanoma patients, and in tumor-infiltrating lymphocytes (TILs) from metastatic melanoma patients. Finally, CD8+ T cell lines from melanoma patients specific for three of the characterized HLA-A *0201 epitopes could recognize melanoma cell lines, which were enhanced by reticular stress. Thus, these peptides may represent a new class of shared TSAs in melanoma and are attractive candidates for evaluation as targets for immunotherapy in preclinical studies. In addition, our selection strategy has the potential to identify new lincRNA-derived antigens in other cancers.

13 November 2023 in bioRxiv
Verified
Preprint
Open access
PDF file
AGAudrey Guilbaud
Audrey Guilbaud
BLBaptiste Lottin
Baptiste Lottin
GCGwenann Cadiou
Gwenann Cadiou
TBTiffany Beauvais
Tiffany Beauvais
SLSylvia Lambot
Sylvia Lambot
FPFrédéric Pecorari
Frédéric Pecorari
Natural killer (NK) cells play a crucial role in the innate immune response to bacterial infections, including those due to Pseudomonas aeruginosa ( P. aeruginosa ) and Staphylococcus aureus ( S. aureus ). In vivo , it has been shown that NK cells are activated by innate accessory cells that detect the presence of bacteria and activate NK cells via a cytokine network. In vitro , several studies have shown that NK cells can also be activated without the help of accessory cells by direct contact with some bacteria species such as extracellular P. aeruginosa . Whether this phenomenon of direct activation is restricted to certain bacterial species, or whether it can be generalized, is still debated, as for example in the case of NK cell activation by S. aureus , which seems to require the intervention of accessory immune cells. Here, we show with co-incubation experiments between NK cells and two bacterial species, that, in the absence of accessory cells, NK cells are able to impede bacterial growth. This has been demonstrated for the P. aeruginosa PA14 strain, which is hypervirulent and known for its deleterious effects on NK cells, as well as for the S. aureus Newman strain. The monitoring of CD107a by flow cytometry suggests that NK cells degranulate after contact with S. aureus bacteria. Our study contributes to the idea that NK cells can be activated in the absence of any accessory cells by various species of bacteria, even an hypervirulent one, and therefore that NKs can directly have an antibacterial effect. This important insight may pave the way for new therapeutic approaches using antibacterial NK-cell engagers.